Debanjan Ray
Vorstandsvorsitzender bei Synthekine, Inc.
Profil
Debanjan Ray is currently the Chief Executive Officer at Synthekine, Inc. and the Director at Normunity, Inc. He also holds the position of Senior VP-Corporate Development & Strategy at CytomX Therapeutics Holdings LLC.
Previously, he worked as an Associate Director-Business Development at Portola Pharmaceuticals, Inc. from 2006 to 2008 and as the Vice President-Business Development at Itero Biopharmaceuticals, Inc. from 2008 to 2011.
He also has experience as a Business Analyst at McKinsey & Co., Inc. and as an Associate at J.P.
Morgan Partners LLC.
From 2011 to 2019, he served as the Chief Financial & Accounting Officer at CytomX Therapeutics, Inc. Mr. Ray completed his undergraduate studies at the Massachusetts Institute of Technology and earned an MBA from The Wharton School of the University of Pennsylvania in 2006.
Aktive Positionen von Debanjan Ray
| Unternehmen | Position | Beginn |
|---|---|---|
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Corporate Officer/Principal | 01.08.2011 |
Synthekine, Inc.
 Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | Vorstandsvorsitzender | 01.05.2019 |
Normunity, Inc.
 Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Direktor/Vorstandsmitglied | 10.07.2023 |
Ehemalige bekannte Positionen von Debanjan Ray
| Unternehmen | Position | Ende |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Finanzdirektor/CFO | 15.05.2019 |
Itero Biopharmaceuticals, Inc.
 Itero Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA. | Corporate Officer/Principal | 01.08.2011 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2008 |
J.P. Morgan Partners LLC
 J.P. Morgan Partners LLC Investment ManagersFinance J.P. Morgan Partners LLC is a private equity firm founded in 1984. The firm headquartered located in New York City. | Corporate Officer/Principal | - |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Debanjan Ray
| Massachusetts Institute of Technology | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Itero Biopharmaceuticals, Inc.
Itero Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
J.P. Morgan Partners LLC
J.P. Morgan Partners LLC Investment ManagersFinance J.P. Morgan Partners LLC is a private equity firm founded in 1984. The firm headquartered located in New York City. | Finance |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Health Technology |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | Health Technology |
Normunity, Inc.
Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Commercial Services |
